date,title,source
Oct-17-18,Eiger BioPharmaceuticals Announces Positive Phase 2 LIMT Study End of Treatment Data with Pegylated Interferon Lambda Monotherapy in Hepatitis Delta Virus (HDV) Infection,PR Newswire
Oct-17-18,"The Daily Biotech Pulse: Eiger's Lymphoedema Drug Study Fails, Roche's Sales Rise",Benzinga
Oct-18-18,Eiger BioPharmaceuticals to Participate at BTIG Biotech Conference,PR Newswire
Oct-18-18,"The Daily Biotech Pulse: Novartis Buys Endocyte, Proteostasis Positive Cystic Fibrosis Trial, 2 IPOs",Benzinga
Oct-22-18,Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock,PR Newswire
Oct-22-18,Eiger BioPharmaceuticals Receives FDA Rare Pediatric Disease (RPD) Designation for Lonafarnib for the Treatment of Progeria and Progeroid Laminopathies and Plans NDA Filing in 2019,PR Newswire
